Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev (nintedanib) treatment in patients with idiopathic pulmonary fibrosis (IPF), a study has found. These results also suggest that lower performance status and a full starting dosage are risk factors…
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the analysis were published in the journal Advances In Therapy in an article titled, “Cardiovascular Risks,…
When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe, a recent study reported. The study,”Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF),” was published in the journal BMC Pulmonary Medicine. As its name…
A less toxic precursor formulation of the chemotherapeutic agent paclitaxel can reduce lung fibrosis in mice with pulmonary fibrosis, a study shows. The finding suggests that this compound, named baccatin III or BAC, has the potential to represent a new treatment strategy for…
The use of oxygen at rest is associated with a greater likelihood of death or lung transplant in people with idiopathic pulmonary fibrosis (IPF), a study shows. The results also showed that lower lung function at the start of the study, as measured by tests like forced vital…
The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). PRM-151 is a recombinant (lab-made) version of the protein pentraxin-2. This protein acts on immune cells called macrophages; it can activate these cells to…
Get regular updates to your inbox.
